Jul 7, 2026
Dr. Ashwin Singh Parihar sits down
with Dr. Louise Emmett to
discuss how post-therapy Lutetium-177 PSMA SPECT/CT may help predict overall survival in
patients with metastatic castration resistant prostate cancer and
shape future treatment decisions. Drawing from the
ENZA-p trial run by ANZUP
cancer trials group, they explore quantitative imaging, treatment
response assessment, adaptive dosing strategies, and the growing
role of theranostics in precision oncology.